ArticleScientific reports2026
End-to-end deep attention-based multitask pipeline for predicting uncertainty-quantified peptide properties from mass spectrometry data.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
3 authors.
Funding
Abstract
Mass-based filtering significantly reduces the peptide candidate pool for subsequent scoring in database search algorithms. While useful, filtering based on one property may lead to exclusion of non-abundant spectra and uncharacterized peptides – potentially exacerbating the streetlight effect. Here we present ProteoRift, a novel attention and multitask deep-network, which can predict multiple peptide properties (length, missed cleavages, and modification status) directly from spectra 77.8% of the time. Integrating ProteoRift into an end-to-end pipeline significantly reduces the search space compared to mass-only filtering. This delivers 8x to 12x speedups while maintaining peptide deduction accuracy comparable to established algorithmic techniques. We also developed uncertainty estimation metrics, which can distinguish between in-distribution and out-of-distribution data (ROC-AUC 0.99) and predict high-scoring mass spectra against the correct peptide (ROC-AUC 0.94). These models and metrics are integrated in an end-to-end pipeline available at https://github.com/pcdslab/ProteoRift .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.